CSIMarket



Sangui Biotech International Inc  (SGBI)
Other Ticker:  
 
 

SGBI's Income from Cont. Operations Growth by Quarter and Year

Sangui Biotech International Inc's Income from Cont. Operations results by quarter and year




SGBI Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter June - -0.05 -0.07 -0.13
III Quarter March -0.02 - -0.03 -0.06
II Quarter December -0.01 -0.08 -0.06 -0.05
I Quarter September -0.03 -0.08 -0.04 -0.10
FY   -0.06 -0.21 -0.20 -0.34



SGBI Income from Cont. Operations third quarter 2022 Y/Y Growth Comment
Sangui Biotech International Inc in the third quarter 2022 recorded loss from continued operations of $ -0.02 millions.

According to the results reported in the third quarter 2022, Sangui Biotech International Inc achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Sangui Biotech International Inc' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2022.




SGBI Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter June - - - -
III Quarter March - - - -
II Quarter December - - - -
I Quarter September - - - -
FY   - - - -

Financial Statements
Sangui Biotech International Inc's third quarter 2022 Income from Cont. Operations $ -0.02 millions SGBI's Income Statement
Sangui Biotech International Inc's third quarter 2021 Income from Cont. Operations $ 0.00 millions Quarterly SGBI's Income Statement
New: More SGBI's historic Income from Cont. Operations Growth >>


SGBI Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter June - - - -
III Quarter March - - - -
II Quarter December - - - -
I Quarter September - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Sangui Biotech International Inc's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SGBI's III. Quarter Q/Q Income from Cont. Operations Comment
Current accomplishment of -0.02 millions by Sangui Biotech International Inc appear even more unfavourable compare to the -0.01 millions loss from continued operations in the previous quarter.

Within Biotechnology & Pharmaceuticals industry Sangui Biotech International Inc achieved highest sequential Income from Cont. Operations growth. While Sangui Biotech International Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SGBI's III. Quarter Q/Q Income from Cont. Operations Comment
Recent accomplishment of -0.02 millions by Sangui Biotech International Inc appear even less good if you take a look at loss from continued operations -0.01 millions in the previous quarter.

Within Biotechnology & Pharmaceuticals industry Sangui Biotech International Inc achieved highest sequential Income from Cont. Operations growth. While Sangui Biotech International Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Sangui Biotech International Inc's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ -0.11 $ -0.09 $ -0.16 $ -0.20 $ -0.22
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment


Sangui Biotech International Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment


Sangui Biotech International Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
SGBI's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for SGBI's Competitors
Income from Cont. Operations Growth for Sangui Biotech International Inc's Suppliers
Income from Cont. Operations Growth for SGBI's Customers

You may also want to know
SGBI's Annual Growth Rates SGBI's Profitability Ratios SGBI's Asset Turnover Ratio SGBI's Dividend Growth
SGBI's Roe SGBI's Valuation Ratios SGBI's Financial Strength Ratios SGBI's Dividend Payout Ratio
SGBI's Roa SGBI's Inventory Turnover Ratio SGBI's Growth Rates SGBI's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2022
Chemed Corporation-1.88%$ -1.882 millions
Biomx Inc.-2.77%$ -2.773 millions
Ironwood Pharmaceuticals inc.-2.82%$ -2.818 millions
Corcept Therapeutics Inc-2.85%$ -2.847 millions
Msa Safety Inc-2.89%$ -2.891 millions
Merit Medical Systems Inc-3.77%$ -3.769 millions
Addus Homecare Corporation-4.77%$ -4.767 millions
Idexx Laboratories Inc-5.05%$ -5.054 millions
Hca Healthcare Inc.-7.28%$ -7.278 millions
National Research Corporation-7.51%$ -7.506 millions
Amgen Inc.-10.33%$ -10.328 millions
Petmed Express Inc.-10.95%$ -10.951 millions
Organon and Co.-11.90%$ -11.899 millions
Regeneron Pharmaceuticals Inc.-12.71%$ -12.706 millions
Intuitive Surgical Inc.-15.12%$ -15.119 millions
Apollo Medical Holdings Inc.-16.50%$ -16.496 millions
Encompass Health Corporation-17.09%$ -17.093 millions
Molecular Templates Inc.-19.30%$ -19.296 millions
Royalty Pharma Plc-19.43%$ -19.434 millions
Natus Medical Inc-20.58%$ -20.576 millions
Fulgent Genetics Inc.-23.49%$ -23.486 millions
Quest Diagnostics Inc-23.88%$ -23.878 millions
Fonar Corporation-24.12%$ -24.122 millions
Hologic Inc-26.49%$ -26.488 millions
Integra Lifesciences Holdings Corp-27.52%$ -27.521 millions
Universal Health Services Inc.-27.77%$ -27.765 millions
National Healthcare Corp-27.97%$ -27.966 millions
Incyte Corp-29.03%$ -29.033 millions
Davita Inc.-29.44%$ -29.439 millions
Reynolds Consumer Products Inc.-29.73%$ -29.730 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CARV's Profile

Stock Price

CARV's Financials

Business Description

Fundamentals

Charts & Quotes

CARV's News

Suppliers

CARV's Competitors

Customers & Markets

Economic Indicators

CARV's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071